Join Growin Stock Community!

鑫品生醫4170.TW Overview

TW StockBiotech. & Medical
(No presentation for 4170)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

鑫品生醫（4170）Overall Performance

鑫品生醫（4170）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

鑫品生醫（4170） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

鑫品生醫（4170）Key Information

鑫品生醫（4170）Profile

Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It offers cell preparation product manufacturing; and collection, processing, and storage management of immune cells. The company's cell preparation products are used in the field of infectious diseases and inflammation, cancer, and tumor diseases. Vectorite Biomedical Inc. was founded in 1993 and is based in New Taipei City, Taiwan.

鑫品生醫（4170）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.68
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.99
PB Ratio
1.57
Price-to-FCF
187.42
METRIC
VALUE
vs. INDUSTRY
Gross Margin
35.09%
Net Margin
-24.08%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.68
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4.99
PB Ratio
1.57
Price-to-FCF
187.42
Gross Margin
35.09%
Net Margin
-24.08%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

4170

鑫品生醫

14.10D

1.42%

(0.01)

  • When is 4170's latest earnings report released?

    The most recent financial report for 鑫品生醫 (4170) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4170's short-term business performance and financial health. For the latest updates on 4170's earnings releases, visit this page regularly.

  • How much cash does 4170 have?

    At the end of the period, 鑫品生醫 (4170) held Total Cash and Cash Equivalents of 13.91M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4170 go with three margins increasing?

    In the latest report, 鑫品生醫 (4170) did not achieve the “three margins increasing” benchmark, with a gross margin of 42.14%%, operating margin of -21.83%%, and net margin of 11.35%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4170's profit trajectory and future growth potential.